Loading stock data…
$4.80+0.21 (+4.58%)
eXoZymes, Inc.
eXoZymes, Inc. in the Healthcare sector is trading at $4.80 with a market capitalization of $59M. The stock is currently near its 52-week low of $4.35, remaining 41.1% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 15 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$2.95M↓ | -$2.39M↑ | -$2.70M↓ | -$2.52M↑ | -$2.55M |
| Net Income | -$2.88M↓ | -$2.37M↑ | -$2.66M↓ | -$2.29M↑ | -$2.36M |
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc...